AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34180141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Metabolic Activators (CMAs) including l-serine, N-acetyl-l-cysteine, nicotinamide riboside, and l-carnitine tartrate
Number of subjects: 0
Study 34180141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34180141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Metabolic Activators (CMAs)
Number of subjects: 0
Study 32007460 — intervention group
Group type: EXPERIMENTAL
Intervention: Mo.Ma Ultra device + Roadsaver stent (Mo.Ma + RS)
Number of subjects: 104
Study 32007460 — intervention group
Group type: COMPARATOR
Intervention: Mo.Ma Ultra device + Carotid Wallstent (Mo.Ma + CW)
Number of subjects: 104
Study 32007460 — intervention group
Group type: COMPARATOR
Intervention: FilterWire device + Roadsaver stent (FW + RS)
Number of subjects: 104
Study 32007460 — intervention group
Group type: COMPARATOR
Intervention: FilterWire device + Carotid Wallstent (FW + CW)
Number of subjects: 104
Study 32007460 — intervention group
Group type: COMPARATOR
Intervention: Carotid Wallstent (CW)
Number of subjects: 104
Study 32007460 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients post-CAS
Number of subjects: 104
Study 36163159 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck/shoulder progressive exercise programme (20 min, 3×/week)
Number of subjects: 484
Study 36163159 — intervention group
Group type: COMPARATOR
Intervention: Health education sessions (60 min, 1×/week)
Number of subjects: 484
Study 33096365 — intervention group
Group type: EXPERIMENTAL
Intervention: Take-home naloxone (THN) kits, including two doses of naloxone
Number of subjects: 22
Study 35811182 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus home exercise program (ST+HEP)
Number of subjects: 190
Study 35811182 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 190
Study 34354655 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-oriented self-management intervention
Number of subjects: 96
Study 34354655 — intervention group
Group type: COMPARATOR
Intervention: Control care
Number of subjects: 96
Study 36384651 — intervention group
Group type: COMPARATOR
Intervention: Animal (omnivorous diet)
Number of subjects: 22
Study 32195861 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group (cephalexin 500 mg every 6 hours for 7 days)
Number of subjects: 124
Study 32195861 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (identical capsules)
Number of subjects: 124
Study 35594693 — intervention group
Group type: COMPARATOR
Intervention: Diet LCPLME (low protein, low energy)
Number of subjects: 40
Study 35594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet LCPHME (low protein, high energy)
Number of subjects: 40
Study 35594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HCPLME (high protein, low energy)
Number of subjects: 40
Study 35594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet MCPLME (medium protein, low energy)
Number of subjects: 40
Study 35594693 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet HCPHME (high protein, high energy)
Number of subjects: 40
Study 34309926 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning (ML) algorithm for automatic classification of fetal occiput position using transperineal ultrasound (TPU) images.
Number of subjects: 1219
Study 35997984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 34689142 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation
Number of subjects: 192
Study 34689142 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser + AmF/NaF/SnCl2 solution
Number of subjects: 192
Study 34689142 — intervention group
Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 192
Study 34689142 — intervention group
Group type: COMPARATOR
Intervention: AmF/NaF/SnCl2 solution
Number of subjects: 192
Study 35151711 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge Franseen needles
Number of subjects: 523
Study 35151711 — intervention group
Group type: COMPARATOR
Intervention: 22-gauge standard needles
Number of subjects: 523
Study 34493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 0
Study 34493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) therapy
Number of subjects: 0
Study 34493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (ImRs) therapy
Number of subjects: 0
Study 34493253 — intervention group
Group type: COMPARATOR
Intervention: 3-month SUD treatment only
Number of subjects: 0
Study 34493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous SUD/PTSD treatment
Number of subjects: 0
Study 34493253 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential SUD/PTSD treatment
Number of subjects: 0
Study 32553435 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock-wave therapy (rESWT)
Number of subjects: 103
Study 32553435 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided low-dose intra-articular steroid injection (20 mg of triamcinolone acetonide)
Number of subjects: 103
Study 35976544 — intervention group
Group type: EXPERIMENTAL
Intervention: UP-Caregiver (transdiagnostic intervention via telehealth)
Number of subjects: 80
Study 35976544 — intervention group
Group type: COMPARATOR
Intervention: Delayed condition (6-weeks after receipt of psychoeducational materials)
Number of subjects: 80
Study 34606752 — intervention group
Group type: EXPERIMENTAL
Intervention: story-based audiovisual mnemonics
Number of subjects: 80
Study 34606752 — intervention group
Group type: COMPARATOR
Intervention: text-reading (control)
Number of subjects: 80
Study 32865004 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 23
Study 32865004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 36216159 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO regression-based prediction equation for appendicular skeletal muscle mass (ASM)
Number of subjects: 1296
Study 36216159 — intervention group
Group type: COMPARATOR
Intervention: BIA-measured ASM
Number of subjects: 1296
Study 32609980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg every 12 hours for 4 to <10 kg, 1000 mg every 12 hours for 10 to <14 kg, 1500 mg every 12 hours for 14 to <20 kg)
Number of subjects: 4002
Study 32609980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matched volume)
Number of subjects: 4002
Study 32609980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 4002
Study 32609980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4002
Study 33369213 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser technique
Number of subjects: 40
Study 33369213 — intervention group
Group type: COMPARATOR
Intervention: Conventional scalpel technique
Number of subjects: 40
Study 35401752 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxabrushes and regular toothbrushes
Number of subjects: 510
Study 35401752 — intervention group
Group type: COMPARATOR
Intervention: Regular toothbrushes only
Number of subjects: 510
Study 32250007 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain consumers
Number of subjects: 392
Study 32250007 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake
Number of subjects: 392
Study 35854942 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivoice chorus intervention
Number of subjects: 50
Study 35854942 — intervention group
Group type: COMPARATOR
Intervention: Simple psychological counseling
Number of subjects: 50
Study 33864736 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-Cav1 vaccine 50 μg with AlOH
Number of subjects: 95
Study 33864736 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-Cav1 vaccine 150 μg with AlOH
Number of subjects: 95
Study 33864736 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-Cav1 vaccine 500 μg with AlOH
Number of subjects: 95
Study 33864736 — intervention group
Group type: EXPERIMENTAL
Intervention: DS-Cav1 vaccine (all doses)
Number of subjects: 95
Study 34352922 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley with concurrent prostaglandin (Foley-PGE)
Number of subjects: 2376
Study 34352922 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley only (Foley)
Number of subjects: 2376
Study 34352922 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley with concurrent oxytocin (Foley-oxytocin)
Number of subjects: 2376
Study 34352922 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin only (PGE)
Number of subjects: 2376
Study 34380538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Number of subjects: 207
Study 34380538 — intervention group
Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 207
Study 32629657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 32629657 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonoperative treatment)
Number of subjects: 0
Study 34425924 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged expressive writing (12 sessions)
Number of subjects: 112
Study 34425924 — intervention group
Group type: COMPARATOR
Intervention: Standard expressive writing (4 sessions)
Number of subjects: 112
Study 33480569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iopamidol at a dose of 480 mg iodine (I)/kg, sampled at 5 min, 1 hr, 6 hr, 24 hr, and 48 hr postinjection.
Number of subjects: 35
Study 33480569 — intervention group
Group type: COMPARATOR
Intervention: Control group received an equivalent volume of saline, sampled at 48 hr.
Number of subjects: 35
Study 35640175 — intervention group
Group type: EXPERIMENTAL
Intervention: Muramyl peptides (200 micrograms administered intramuscularly daily for 7 days)
Number of subjects: 60
Study 35640175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 60
Study 32871947 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation, great saphenous vein stripping, and subfascial perforator vein surgery with sterilized electric pneumatic tourniquet and Esmarch's bandage
Number of subjects: 274
Study 32871947 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (control group)
Number of subjects: 274
Study 35938325 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with conventional western medicine therapy
Number of subjects: 60
Study 35938325 — intervention group
Group type: COMPARATOR
Intervention: Conventional western medicine therapy
Number of subjects: 60
Study 32805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with MVD
Number of subjects: 2083
Study 32805324 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients with MVD
Number of subjects: 2083
Study 32805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with single vessel disease (SVD)
Number of subjects: 2083
Study 32805324 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients with single vessel disease (SVD)
Number of subjects: 2083
Study 32805324 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diabetic patients
Number of subjects: 2083
Study 32805324 — intervention group
Group type: COMPARATOR
Intervention: Overall non-diabetic patients
Number of subjects: 2083
Study 32221020 — intervention group
Group type: EXPERIMENTAL
Intervention: TROMP operation
Number of subjects: 208
Study 32221020 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytoreductive method
Number of subjects: 208
Study 33633231 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine
Number of subjects: 46
Study 33633231 — intervention group
Group type: COMPARATOR
Intervention: 0.25% levobupivacaine
Number of subjects: 46
Study 32403906 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidif plus® (two tablets per day for 7 days)
Number of subjects: 88
Study 32403906 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (two consecutive days)
Number of subjects: 88
Study 35040415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg OD or 200 mg BID
Number of subjects: 99
Study 35040415 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (Control)
Number of subjects: 99
Study 35040415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 99
Study 35040415 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) and Pioglitazone (Control)
Number of subjects: 99
Study 33551284 — intervention group
Group type: EXPERIMENTAL
Intervention: Active 20 Hz rTMS applied to the bilateral DLPFC
Number of subjects: 83
Study 33551284 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 83
Study 32539079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm treatment (25 Necator americanus larvae transcutaneously)
Number of subjects: 71
Study 32539079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 32539079 — intervention group
Group type: EXPERIMENTAL
Intervention: Hookworm treatment
Number of subjects: 71
Study 33660875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily for 4 weeks
Number of subjects: 14
Study 33660875 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 14
Study 32534626 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-SARS-CoV-2 IgG antibodies testing
Number of subjects: 2766
Study 34747568 — intervention group
Group type: EXPERIMENTAL
Intervention: simplified team-based learning (sTBL)
Number of subjects: 179
Study 34747568 — intervention group
Group type: COMPARATOR
Intervention: interactive lectures (IL)
Number of subjects: 179
Study 34076308 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (1 μg for 1 week before surgery)
Number of subjects: 47
Study 34076308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32590010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic Bétadine™ 5% with iodine-impregnated 3M™ Ioban2™
Number of subjects: 30
Study 32590010 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic chlorhexidine 0.5%
Number of subjects: 30
Study 32590010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical cleansing and sterile draping
Number of subjects: 30
Study 32590010 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative shower
Number of subjects: 30
Study 35021257 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Villalta Scale version 2 (PRV2)
Number of subjects: 181
Study 35021257 — intervention group
Group type: COMPARATOR
Intervention: Original Villalta scale
Number of subjects: 181
Study 33751644 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth disinfection (FMD) with splinting of teeth 33–43
Number of subjects: 34
Study 33751644 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth disinfection (FMD) without splinting (control group)
Number of subjects: 34
Study 32367730 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted alcohol consumption
Number of subjects: 94
Study 35113137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan monthly (15 mg)
Number of subjects: 167
Study 35113137 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegcetacoplan every other month (15 mg)
Number of subjects: 167
Study 35113137 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 167
Study 33498220 — intervention group
Group type: EXPERIMENTAL
Intervention: High NO3‐, low NO2‐ (HL; 572 mg NO3‐, 32 mg NO2‐)
Number of subjects: 11
Study 33498220 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium NO3‐, medium NO2‐ (MM; 280 mg NO3‐, 237 mg NO2‐)
Number of subjects: 11
Study 33498220 — intervention group
Group type: EXPERIMENTAL
Intervention: Low NO3‐, medium NO2‐ (LM; 43 mg NO3‐, 262 mg NO2‐)
Number of subjects: 11
Study 33498220 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL; low NO3‐, low NO2‐: 8 mg NO3‐, 5.8 mg NO2‐)
Number of subjects: 11
Study 33630620 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message during personality test
Number of subjects: 1447
Study 33630620 — intervention group
Group type: COMPARATOR
Intervention: Control message during personality test
Number of subjects: 1447
Study 34962245 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic group (AG)
Number of subjects: 57
Study 34962245 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based group (LG)
Number of subjects: 57
Study 34962245 — intervention group
Group type: COMPARATOR
Intervention: Home group (HG)
Number of subjects: 57
Study 36323122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges (students set a goal regarding their effort in not throwing away plastic products)
Number of subjects: 0
Study 36323122 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosts (students wrote an essay to increase empathy for parties impacted by environmental issues)
Number of subjects: 0
Study 36323122 — intervention group
Group type: EXPERIMENTAL
Intervention: Both nudges and boosts
Number of subjects: 0
Study 36323122 — intervention group
Group type: COMPARATOR
Intervention: None (neither nudges nor boosts)
Number of subjects: 0
Study 32700186 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention delivered to daycare providers and parents
Number of subjects: 215
Study 32700186 — intervention group
Group type: COMPARATOR
Intervention: Standard daycare curriculum (COM)
Number of subjects: 215
Study 32747931 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral surotomycin (250 mg twice daily)
Number of subjects: 1147
Study 32747931 — intervention group
Group type: COMPARATOR
Intervention: Oral vancomycin (125 mg four times per day)
Number of subjects: 1147
Study 36450593 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (SG)
Number of subjects: 7297
Study 36450593 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 7297
Study 36450593 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 7297
Study 33734043 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 22
Study 33734043 — intervention group
Group type: COMPARATOR
Intervention: Control (no anti-inflammatory therapy)
Number of subjects: 22
Study 33926433 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 36
Study 33926433 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 36
Study 32201165 — intervention group
Group type: EXPERIMENTAL
Intervention: BPSS app
Number of subjects: 102
Study 32201165 — intervention group
Group type: COMPARATOR
Intervention: No-BPSS app
Number of subjects: 102
Study 32201165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 35354247 — intervention group
Group type: EXPERIMENTAL
Intervention: DARA SC
Number of subjects: 522
Study 35354247 — intervention group
Group type: COMPARATOR
Intervention: DARA IV
Number of subjects: 522
Study 34538546 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of 8-mg intravenous dexamethasone (1D-group)
Number of subjects: 115
Study 34538546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 8-mg intravenous dexamethasone (2D-group)
Number of subjects: 115
Study 32958699 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX or FOLFIRI combined with cetuximab
Number of subjects: 613
Study 32958699 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX or FOLFIRI combined with bevacizumab
Number of subjects: 613
Study 32958699 — intervention group
Group type: EXPERIMENTAL
Intervention: rs11649255 in AXIN1
Number of subjects: 613
Study 32105355 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐PRESCRIBE (NSAIDs)
Number of subjects: 100
Study 32105355 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 36183982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% M. oleifera leaf extract
Number of subjects: 0
Study 36183982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% or 0.75% M. oleifera leaf extract
Number of subjects: 0
Study 36183982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35%‐0.48% M. oleifera leaf extract
Number of subjects: 0
Study 34648568 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality (IVR) intervention for three sessions: 4 hours before chemotherapy, 5 minutes before and during the first course chemotherapy, and 5 minutes before and during the second course chemotherapy.
Number of subjects: 20
Study 34648568 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (Control group).
Number of subjects: 20
Study 32536538 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal lidocaine-prilocaine formulation
Number of subjects: 40
Study 32536538 — intervention group
Group type: COMPARATOR
Intervention: Non-liposomal lidocaine-prilocaine formulation
Number of subjects: 40
Study 35698000 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD) 75/75/150 mg
Number of subjects: 84
Study 35698000 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD) 75/150/300 mg
Number of subjects: 84
Study 34027851 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleNP
Number of subjects: 150
Study 34027851 — intervention group
Group type: COMPARATOR
Intervention: F‐F
Number of subjects: 150
Study 34027851 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleNP and F‐F
Number of subjects: 150
Study 33713826 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge low-molecular-weight heparin (LMWH) injections once-daily for 30 days
Number of subjects: 133
Study 33713826 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections once-daily for 30 days
Number of subjects: 133
Study 34787919 — intervention group
Group type: EXPERIMENTAL
Intervention: TMFI treatment (Tixel®, Novoxel®, Israel)
Number of subjects: 68
Study 34787919 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFL treatment (non‐ablative fractional 1565 nm laser, ResurFX®, Lumenis, Israel)
Number of subjects: 68
Study 34787919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TMFI and NAFL treatments
Number of subjects: 68
Study 32173636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline combined with oxiracetam
Number of subjects: 120
Study 32173636 — intervention group
Group type: COMPARATOR
Intervention: Nicergoline alone
Number of subjects: 120